REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Analyst sentiment is moderately positive: Nine of 13 analysts rate REGENXBIO a buy, three recommend holding and one rates it a sell. The average 12-month price target is $23.27, well above the reported share price of $8.15.
• REGENXBIO beat quarterly expectations, reporting EPS of $0.43 versus the $0.08 consensus and revenue of $108.02 million versus $97.63 million expected. Analysts nevertheless forecast a full-year loss of $3.91 per share.
• Institutional investors own 88.08% of the stock, while insiders own 14.22%; insiders have sold 58,494 shares worth approximately $718,232 over the past 90 days.

REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) has earned an average rating of "Moderate Buy" from the thirteen analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $23.2727.

A number of research analysts have recently issued reports on RGNX shares. Wall Street Zen upgraded shares of REGENXBIO from a "strong sell" rating to a "hold" rating in a research note on Saturday, August 8th. Barclays cut REGENXBIO from an "overweight" rating to a "hold" rating in a research report on Friday, August 7th. Zacks Research raised REGENXBIO from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 12th. Robert W. Baird decreased their price target on REGENXBIO from $32.00 to $29.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 25th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of REGENXBIO in a research note on Friday, September 4th.

REGENXBIO Stock Performance

Shares of RGNX opened at $8.15 on Wednesday. REGENXBIO has a fifty-two week low of $5.45 and a fifty-two week high of $16.19. The firm has a 50-day simple moving average of $9.75 and a 200-day simple moving average of $9.22. The company has a market capitalization of $537.98 million, a price-to-earnings ratio of -2.15 and a beta of 0.94.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.08 by $0.35. REGENXBIO had a negative return on equity of 220.07% and a negative net margin of 112.58%.The firm had revenue of $108.02 million during the quarter, compared to the consensus estimate of $97.63 million. Equities research analysts forecast that REGENXBIO will post -3.91 EPS for the current year.

Insider Activity

In other news, insider Steve Pakola sold 36,725 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $12.86, for a total value of $472,283.50. Following the completion of the transaction, the insider owned 213,009 shares in the company, valued at $2,739,295.74. This trade represents a 14.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last ninety days, insiders have sold 58,494 shares of company stock valued at $718,232. Company insiders own 14.22% of the company's stock.

Institutional Investors Weigh In On REGENXBIO

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Versant Capital Management Inc grew its holdings in REGENXBIO by 60.4% in the second quarter. Versant Capital Management Inc now owns 2,741 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 1,032 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of REGENXBIO in the second quarter valued at $51,000. Legal & General Group Plc acquired a new position in shares of REGENXBIO during the 2nd quarter worth $56,000. Entropy Technologies LP acquired a new position in shares of REGENXBIO during the 1st quarter worth $87,000. Finally, ProShare Advisors LLC purchased a new stake in shares of REGENXBIO in the 4th quarter worth about $155,000. 88.08% of the stock is currently owned by institutional investors and hedge funds.

REGENXBIO Company Profile

REGENXBIO Inc is a biotechnology company focused on developing gene therapies for serious diseases with limited treatment options. The company uses its proprietary NAV AAV Gene Delivery Platform to design adeno-associated virus (AAV) vectors intended to deliver therapeutic genes to targeted cells and tissues.

REGENXBIO's pipeline has included investigational therapies for rare and genetic disorders, including Duchenne muscular dystrophy, Hunter syndrome, severe mucopolysaccharidosis type I, and homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.